Benefit of adjuvant BMA (bone modifying agents, meaning bisphosphonates and denosumab) in eBC
e-ESO Podcasts - Un pódcast de ESO - European School of Oncology
Categorías:
Expert: Michael Gnant, Comprehensive Cancer Center Vienna, Vienna, Austria Questions: 1.What is the recommendation for use of bisphosphonates in eBC? Which agents? How long? To which patients? 2.What is the benefit of adjuvant bisphosphonates in eBC (breast cancer - related outcomes and other benefit)? 3.What is the recommendation for use of denosumab in eBC? 4.What are the data to support these recommendations for practice?
